home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409a.zip
/
M9490061.TXT
< prev
next >
Wrap
Text File
|
1994-09-03
|
3KB
|
48 lines
Document 0061
DOCN M9490061
TI Immunomodulation by levamisole in patients with recurrent aphthous
ulcers or oral lichen planus.
DT 9411
AU Sun A; Chiang CP; Chiou PS; Wang JT; Liu BY; Wu YC; School of Dentistry,
National Taiwan University, Taipei, ROC.
SO J Oral Pathol Med. 1994 Apr;23(4):172-7. Unique Identifier : AIDSLINE
MED/94322276
AB The purpose of this study was to evaluate the effect of levamisole on
the immune system of patients with recurrent aphthous ulcers (RAU) or
oral lichen planus (OLP) in an open trial. Lymphocyte subsets, serum
immunoglobulins, and circulating immune complexes (CIC) in patients with
RAU or OLP and in normal control subjects were determined by an indirect
immunofluorescence (IIF) technique with monoclonal anti-lymphocyte
antibodies, by single radial immunodiffusion, and by precipitation with
3% polyethylene glycol, respectively. In addition, the anti-nuclear
antibodies (ANA) and anti-basal cell antibodies (anti-BCA) in sera were
detected by an IIF technique. We found a significant improvement in
clinical symptoms and normalization of the decreased CD4/CD8 ratio in
RAU patients after levamisole treatment. Moreover, the decreased CD4/CD8
ratio, which persisted until the remission stage in the untreated RAU
patients, reverted to normal in the active late stage in the
levamisole-treated patients. This reversion of aberrant cellular
immunity in an earlier stage of the ulcer cycle may explain why RAU
patients experience symptom improvement after levamisole treatment.
Although RAU patients treated with levamisole for 1 to 3 or 4 months
still had higher than normal levels of CIC and serum immunoglobulins,
the levels of their IgA and IgM returned to normal values after 4 months
of levamisole treatment. The serum ANA detected in 6 patients with RAU
and 3 patients with erosive OLP disappeared after 1-22 months of
levamisole treatment. The disappearance of serum anti-BCA was also
observed in 50% of the anti-BCA-positive patients with erosive OLP after
3-13 months of levamisole treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
DE Adolescence Adult Aged Antibodies, Antinuclear/BLOOD/DRUG EFFECTS
Antigen-Antibody Complex/BLOOD/DRUG EFFECTS Case-Control Studies Child
CD4-CD8 Ratio/DRUG EFFECTS Female Human IgA/BLOOD/DRUG EFFECTS
IgG/BLOOD/DRUG EFFECTS IgM/BLOOD/DRUG EFFECTS Immunoglobulins/*DRUG
EFFECTS Levamisole/*THERAPEUTIC USE Lichen Planus, Oral/DRUG
THERAPY/*IMMUNOLOGY Male Middle Age Stomatitis, Aphthous/DRUG
THERAPY/*IMMUNOLOGY T-Lymphocyte Subsets/*DRUG EFFECTS T-Lymphocytes,
Cytotoxic/DRUG EFFECTS T-Lymphocytes, Helper-Inducer/DRUG EFFECTS T4
Lymphocytes/DRUG EFFECTS JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).